Current chemotherapeutic possibilities in pancreaticobiliary cancer

Annals of Oncology

Volumn 10, Issue SUPPL. 4, 1999, Pages

  Van Riel, J M G H ^a   Van Groeningen, C J ^a   Pinedo, H M ^a   Giaccone, G ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

5 fluorouracil; Chemotherapy; Gemcitabine; Pancreatic cancer; Pancreaticobiliary cancer

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CISPLATIN; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; MITOMYCIN C; PACLITAXEL; RALTITREXED; STREPTOZOCIN; TEMOZOLOMIDE; TOPOTECAN;

BILIARY TRACT CANCER; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; INTRATUMORAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MULTIMODALITY CANCER THERAPY; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0032803162     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/10.suppl_4.S157     Document Type: Conference Paper

References (54)

1. Gudjonsson B. Carcer of the pancreas: 50 years of surgery. Cancer 1987; 60:2284-303.
2. Willet CG, Lewandrowski K, Warshaw AL et al. Resection margins in carcinoma of the head of the pancreas. Implications for radiotherapy. Ann Surg 1993; 217:144-8.
3. Evans DB, Abbruzzese JL, Rich TA. Cancer of the pancreas. In Cancer: Principles & Practice of Oncology. Edited by DeVita VT, Hellman S, Rosenberg SA. Philadelphia: JB Lippincott Co 1997;1054-87.
4. Rosenberg L. Treatment of pancreatic cancer. Promises and problems of tamoxifen, somatostatine analogs and gemcitabine. Int J Pancreatology 1997; 22:81-93.
5. Griffin JF, Smalley SR, Jewell W et al. Patterns of failure after curative resection of pancreatic carcinoma. Cancer 1990; 66:56-61.
6. Palmer KR, Kerr M, Knowless G et al. Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg 1994; 81:882-85.
7. Glimelius B, Hoffman K, Sjoden PO et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996; 7:593-600.
8. Rosewicz S, Wiedenmann B. Pancreatic carcinoma. Lancet 1997; 349:485-89.
9. Perez MM, Newcomer AD, Moertel CG et al. Assessment of weight loss, food intake, fat metabolism, malabsorption, and treatment of pancreatic insufficiency in pancreatic cancer. Cancer 1983; 52:346-52.
10. Rothenberg ML, Abbruzzese JL, Moore M et al. A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma. Cancer 1996; 78:627-32.
11. Ahlgren JD. Chemotherapy for pancreatic carcinoma. Cancer 1996; 78:653-63.
12. Andersen JS, Burris HA, Casper E et al. Development of a new system for assessing clinical benefit for patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol 1994; 13:A1600.
13. Gelber RD. Gemcitabine for pancreatic cancer: how hard to look for clinical benefit? An American perspective. Ann Oncol 1996; 7:335-7.
14. Verweij J. The benefit of clinical benefit: A European perspective. Ann Oncol 1996; 7:333-4.
15. Crown J, Casper ES, Botet J et al. Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma. J Clin Oncol 1991; 9:1682-6.
16. DeCaprio JA, Mayer RJ, Gonin R et al. Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial. J Clin Oncol 1991; 9:2128-33.
17. Scheithauer W, Pfeffel F, Kornek G et al. A phase II trial of 5-fluorouracil, leucovorin, and recombinant alpha-2 interferon in advanced adenocarcinoma of the pancreas. Cancer 1992; 70:1864-6.
18. Pazdur R, Ajani JJ, Abbruzzese JL et al. Phase II evaluation of fluorouracil and recombinant α-2a-interferon in previously untreated patients with pancreatic adenocarcinoma. Cancer 1992; 70:2073-6.
19. Cullinan SA, Moertel CG, Fleming TR et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA 1985; 253:2061-7.
20. Oster MW, Gray R, Panasci L et al. Chemotherapy for advanced pancreatic cancer. A comparison of 5-fluorouracil, adriamycin, and mitomycin (FAM) with 5-fluorouracil, streptozotocin, and mitomycin (FSM). Cancer 1986; 57:29-33.
21. Cullinan S, Moertel CG, Wieand HS et al. A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallison regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. Cancer 1990; 65:2207-12.
22. Kelsen D, Hudis C, Niedzwiecki D et al. A phase III comparison trial of streptozocin, mitomycin, and fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma. Cancer 1991; 68:965-9.
23. Auerbach M, Wampler GL, Lokich JJ et al. Treatment of advanced pancreatic cancer with a combination of protracted infusional 5-fluorouracil and weekly carboplatin: a mid-atlantic oncology program study. Ann Oncol 1997; 8:439-44.
24. Rothman H, Cantrell JE, Lokich J et al. Continouos infusion 5-fluorouracil plus weekly cisplatin for pancreatic carcinoma: a mid-atlantic oncology program study. Cancer 1991; 68:264-8.
25. Brown T, Tangen C, Fleming T et al. A phase II trial of taxol and granulocyte colony stimulating factor (G-CSF) in patients with adenocarcinoma of the pancreas. Proc Am Soc Clin Oncol 1993:265a.
26. Okada S, Taguchi T. Phase II trial of docetaxel (taxotere) as first-line chemotherapy in patients with metastatic pancreatic cancer: A Japanese cooperative study. Proc Am Soc Clin Oncol 1998:265a.
27. Kouroussis Ch, Kakolyris S, Samelis G et al. Treatment of advanced pancreatic cancer (APC) with docetaxel (D): a multicenter phase II study. Proc Am Soc Clin Oncol 1998; 266a.
28. Scher R, Kosierowski R, Lusch C et al. Phase II trial of topotecan in advanced or metastatic adenocarcinoma of the pancreas. Invest New Drugs 1996; 13:347-54.
29. Pazdur R, Meropol NJ, Casper ES et al. Phase II trial of ZD1694 (Tomudex™*) in patients with advanced pancreatic cancer. Invest New Drugs 1996; 13:355-8.
30. Moore MJ, Feld R, Hedley D et al. A phase II study of temozolomide in advanced untreated pancreatic cancer. Invest New Drugs 1998; 16:77-9.
31. Casper ES, Green MR, Kelsen DP et al. Phase II trial of gemcitabine (2′,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994;12:29-34.
32. Rothenberg ML, Moore MJ, Cripps MC et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996; 7:347-53.
33. Burris III HA, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15:2403-13.
34. Moertel CG, Frytak S, Hahn RG et al. Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads) + 5-fluorouracil, and high dose radiation + 5-fluorouracil. Cancer 1981: 48;1705-10.
35. Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: Comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 1988: 80;751-5.
36. Klaassen DJ, MacIntyre JM, Catton GE et al. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil - an Eastern Cooperative Oncology Group Study. J Clin Oncol 1985: 3;373-8.
37. Jessup JM, Steele G, Mayer RJ et al. Neoadjuvant therapy for unresectable pancreatic adenocarcinoma. Arch Surg 1993: 128;559-64.
38. Kamthan AG, Morris JC, Dalton J et al. Combined modality therapy for stage II and stage III pancreatic carcinoma. J Clin Oncol 1997: 15:2920-27.
39. Blackstock AW, Bernard SA, Savage P et al. Phase I study of concurrent radiation and twice weekly gemcitabine in advanced/metastatic pancreatic cancer. Proc Am Soc Oncol 1998: 264a.
40. McGinn CJ, Smith DC, Szarka CE et al. A phase I study of gemcitabine (gem) in combination with radiation therapy (RT) in patients with localized unresectable pancreatic cancer. Proc Am Soc Oncol 1998: 264a.
41. Neoptoletnos JP, Kerr DJ. Adjuvant therapy for pancreatic cancer. Br J Surg 1995: 82; 1012-4.
42. Andren-Sandberg A, Backman PL, Andersson P. Results of adjuvant chemotherapy in resected pancreatic cancer. Int J Pancreatol 1997: 21;31-8.
43. Kalser MH, Susan SE. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985: 120; 899-903.
44. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 1987: 59;2006-10.
45. Bakkevold KE, Arnesjo B, Dahl O et al. Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of vater-results of a controlled, prospective, randomized multicentre study. Eur J Cancer 1993: 29A: 698-703.
46. Spitz FR, Abbruzzese JL, Lee JE et al. Preoperative and postoperaqtive chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol 1997: 15;928-37.
47. Staley CA, Lee JE, Cleary KR et al. Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head. Am J Surg 1996: 171;118-25.
48. Clary BM, Lyerly HK. Gene therapy and pancreatic cancer. Surg Oncol Clin North AM 1998: 7;217-49.
49. Mulvihill SJ, Warren RS, Fell S et al. A phase I trial of intratumoral injection with an E1B-attenuated adenovirus, ONYX-015, into unresectable carcinomas of the exocrine pancreas. Proc Am Soc Clin Oncol 1998:211a.
50. Miller AR, Robinson EK, Lee JE et al. Neoadjuvant chemoradiation for adenocarcinoma of the pancreas. Surg Oncol Clin North AM 1998: 7;183-97.
51. Thuluvath PJ, Rai R, Venbrux AC et al. Cholangiocarcinoma: A review. Gastroenterologist 1997: 5;306-15.
52. Patt YZ, Jones DV, Hoque A et al. Phase II trial of intravenous fluorouracil and subcutaneous interferon alfa-2b for biliary tract cancer. J Clin Oncol 1996: 14;2311-15.
53. Falkson G, MacIntyre JM, Moertel CG: Eastern Cooperative Oncology Group experience with chemotherapy for inoperative gallbladder and bile duct cancer. Cancer 1984: 54;965-9.
54. Jones DV, Lozano R, Hoque A et al. Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas. J Clin Oncol 1996: 14;2306-10.